While formal pharmacokinetic studies of GLP-1RA co-administration with these IBD drugs have not been conducted, clinicians should monitor for unexplained changes in therapeutic response, particularly during GLP-1RA initiation and dose escalation, and consider staggering oral medications when feasible
The most reported adverse events were gastrointestinal (nausea, vomiting, diarrhea, and constipation)
Administered in mice, the treatment inhibits an enzyme linked to the disease and to insulin resistance
When it comes to the cost, its worth noting that these medications are expensive, but they may be covered by insurance (even online) if you meet the above health criteria
Nausea, constipation, diarrhea, and reflux are commonly reported